Hypertension and Its Clinical Impact: A Report From the 2008 ACC CME

Author Information and Disclosures

Release Date: May 13, 2008; Valid for credit through May 13, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

© Copyright 2008 American Society of Hypertension, Inc.
Pfizer
Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Review the clinical developments presented at the American College of Cardiology meeting.
  2. Describe recent developments in cardiology.
  3. Discuss data with fixed-dose combination therapy that address multiple cardiovascular risk targets to manage global risk.
  4. Discuss the rationale for the first-line use of antihypertensive combination therapy.
Authors and Disclosures

Jackson T. Wright, Jr., MD, PhD
Disclosure: Jackson T. Wright, Jr., MD, PhD, has disclosed that he has received grants-in-aid from GlaxoSmithKline.


David Good
Disclosure: David Good has disclosed no relevant financial relationships.
 
American Society of Hypertension
The American Society of Hypertension is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

ASH designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.